- Home
- EFC vs VRDN Comparison
EFC vs VRDN Comparison
Compare EFC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFC
- VRDN
- Stock Information
- Founded
- EFC 2007
- VRDN 2006
- Country
- EFC United States
- VRDN United States
- Employees
- EFC N/A
- VRDN N/A
- Industry
- EFC Real Estate
- VRDN Medical Specialities
- Sector
- EFC Finance
- VRDN Health Care
- Exchange
- EFC Nasdaq
- VRDN Nasdaq
- Market Cap
- EFC 1.4B
- VRDN 1.6B
- IPO Year
- EFC 2010
- VRDN N/A
- Fundamental
- Price
- EFC $13.44
- VRDN $20.94
- Analyst Decision
- EFC Strong Buy
- VRDN Strong Buy
- Analyst Count
- EFC 7
- VRDN 11
- Target Price
- EFC $14.46
- VRDN $38.80
- AVG Volume (30 Days)
- EFC 1.6M
- VRDN 626.5K
- Earning Date
- EFC 11-05-2025
- VRDN 11-11-2025
- Dividend Yield
- EFC 11.60%
- VRDN N/A
- EPS Growth
- EFC N/A
- VRDN N/A
- EPS
- EFC 1.24
- VRDN N/A
- Revenue
- EFC $312,485,000.00
- VRDN $305,000.00
- Revenue This Year
- EFC N/A
- VRDN N/A
- Revenue Next Year
- EFC $7.92
- VRDN $34,076.08
- P/E Ratio
- EFC $10.86
- VRDN N/A
- Revenue Growth
- EFC 10.76
- VRDN 5.90
- 52 Week Low
- EFC $11.12
- VRDN $9.90
- 52 Week High
- EFC $14.40
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- EFC 56.21
- VRDN 60.40
- Support Level
- EFC $12.75
- VRDN $20.69
- Resistance Level
- EFC $13.50
- VRDN $21.99
- Average True Range (ATR)
- EFC 0.22
- VRDN 0.91
- MACD
- EFC 0.04
- VRDN 0.06
- Stochastic Oscillator
- EFC 92.67
- VRDN 68.38
About EFC Ellington Financial Inc.
Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. it acquires reverse mortgage loans both through its origination activities and through secondary market purchases.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).